Recommended dose is 200 mg every 2 weeks as a subcutaneous injection1
KEVZARA can be used with or without MTX or other conventional DMARDs1*
Reduce the dose to 150 mg once every 2 weeks for the management of neutropenia, thrombocytopenia, or elevated liver enzymes1
Click here for dosing considerations for patient management
*Dosing of MTX and other conventional DMARDs may vary.
Please click on the "Instructions for Use" (IFU) link above for further information.
KEVZARA is available by prescription only.
The KEVZARA packaging, prefilled pen and prefilled syringe received the Arthritis Foundation Ease of Use Commendation after independent testing by experts and evaluation by people with arthritis. Products receiving the Commendation make certain aspects of life easier for people with RA.3,4
DMARD=disease-modifying antirheumatic drug.
References: 1. KEVZARA [prescribing information]. Bridgewater, NJ: Sanofi/Regeneron Pharmaceuticals, Inc; 2018. 2. Kivitz A, Baret-Cormel L, van Hoogstraten H et al. Usability and patient preference phase 3 study of the sarilumab pen in patients with active moderate-to-severe rheumatoid arthritis. Rheumatol Ther. 2017. doi:10.1007/s40744-017-0090-2. 3. Ease of use products. Arthritis Foundation website. http://www.arthritis.org/living-with-arthritis/tools-resources/ease-of-use. Accessed October 10, 2017. 4. Data on file, Sanofi/Regeneron. Regeneron Sarilumab Evaluation Report of Consumer Product Accessibility for Users with Arthritis. February 2015.